Cofepris detects internal corruption network; company benefited from medicines

The Federal Commission for the Protection against Sanitary Risks (Cofepris) reported that it detected an internal network of corruption which favored a company to issue resolutions in its favor.

However, he did not make public the name of the company involved or the drugs or products that received “less strict evaluations” to approve them. health register.

“While other companies were subject to excessive and unnecessary requirements,” he said.

Read also Cofepris issues alert to suspend use of medication for heart conditions

Cofepris announced that when it detected the internal corruption network, files and resolutions related to authorized third parties assisting in health control, such as testing laboratories and laboratories for testing interchangeability of medicines.


{{#values}}
{{#ap}}

{{/ap}} {{^ap}}

{{/ap}}
{{/values}}


“During the analysis, discrepancies were found in the evaluation criteria and interpretation of the required requirements. In addition, it was found that at least one company was favored by less rigorous evaluations, while others faced unjustified overregulation,” he explained.

The regulatory body assured that it will immediately correct the decisions related to auxiliary companies in health control and will take measures to resolve the problems that affected other authorized third parties.

Read also Cofepris to lead conference on pharmaceutical regulation


Join our channel

EL UNIVERSAL is now on WhatsApp! From your mobile device, find out about the most relevant news of the day, opinion articles, entertainment, trends and more.

mahc/rmlgv

 
For Latest Updates Follow us on Google News
 

-

PREV Wilman Terán will be in the Assembly; SNAI started operation for transfer
NEXT Democratic platform commits to Puerto Rico status project that excludes the Commonwealth